Research programme: telomere targeting compounds - MAIA Biotechnology
Alternative Names: RiboTHIO - MAIA Biotechnology; Second generation telomere targeting agents; second-generation THIO analoguesLatest Information Update: 28 Aug 2026
At a glance
- Originator MAIA Biotechnology
- Class Antineoplastics; Small molecules
- Mechanism of Action Telomerase modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2026 No recent reports of development identified for research development in Cancer in USA
- 13 Aug 2025 MAIA Biotechnology has patent protection for mercaptopurine ribonucleoside analogues in Europe
- 02 Aug 2022 MAIA Biotechnology plans to initiate clinical trials by end of 2024 (MAIA Biotechnology website, July 2022)